Glasgow Biotech Mironid Scores $46M to Fight Rare Kidney Disease

Jan de Vries · 2026-08-07

A Scottish biotech company just landed a major financial boost in its quest to tackle one of the most common inherited kidney disorders. Mironid, headquartered in Glasgow, has closed a $46 million Series B financing round to advance its lead drug candidate for Autosomal Dominant Polycystic Kidney Disease (ADPKD) through clinical development. The round was spearheaded by the Scottish National Investment Bank, with strong backing from a syndicate of existing investors, including Roche Venture Fund, Epidarex Capital, Sofinnova Partners, BioGeneration Ventures, and the University of Strathclyde. This vote of confidence signals real momentum for the company's innovative approach. ### Why ADPKD Matters ADPKD isn't just a niche medical condition. It's the most common hereditary kidney disorder worldwide, affecting over 12 million people. The numbers are sobering: half of all patients develop kidney failure by age 60. That's a staggering statistic that underscores the urgent need for better treatment options. Neil Wilkie, CEO of Mironid, emphasized the significance of this funding. "Securing funding from such a high-calibre syndicate is a strong validator of our approach to treating kidney diseases such as ADPKD," he said. "This financing will allow us to progress the clinical development of our lead candidate, bringing us closer to transforming the treatment landscape for patients with rare kidney diseases." ### The Science Behind the Hope Mironid's journey began in 2015 as a spinout from the University of Strathclyde and Heriot-Watt University. It builds on over three decades of research into PDE biology by Professor Miles Houslay. The company focuses on developing drug candidates for degenerative and rare genetic kidney diseases, along with major inflammatory conditions and cancer. The star of the show is Mironid's first-in-class LoAc small molecule candidate. Here's how it works: - It directly targets cyclic AMP (cAMP), a cellular signal active throughout all disease stages - cAMP drives both cell proliferation and fluid secretion within kidney cysts - The approach aims to prevent new cyst formation and arrest growth of existing ones Preclinical data has shown significant efficacy and a favorable safety profile, including reductions in cyst number and kidney volume. The company believes this cAMP-modulating strategy could offer a more durable treatment option with an improved side-effect profile compared to existing therapies. ### Beyond ADPKD Mironid isn't putting all its eggs in one basket. The pipeline also targets phosphodiesterase 4 (PDE4) enzymes, which play a key role in cell signaling pathways implicated in disease progression. Led by an industry-experienced management team, the company operates on a research-and-development-led model, funded through venture capital and strategic investment. Paul Callaghan, Investment Director at the Scottish National Investment Bank, captured the broader significance: "Mironid exemplifies Scotland's growing reputation for biotech innovation, developing a new treatment approach that could improve options for people living with kidney disease. We are pleased to join a committed group of investors to support the company through this critical stage of development." ### What's Next With this fresh capital, Mironid is well-positioned to push its lead candidate through clinical trials. The funding follows an earlier Series A extension round that brought the company's total funding since inception to roughly $47 million. For patients living with ADPKD, this progress represents genuine hope for a future with better, more targeted treatment options. The road from lab bench to patient bedside is long, but Mironid just took a significant step forward.